| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
|
Cancer Res
|
1999
|
2.70
|
|
2
|
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
|
Blood
|
2001
|
2.25
|
|
3
|
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
|
Cancer Res
|
1999
|
1.62
|
|
4
|
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
|
J Clin Endocrinol Metab
|
2001
|
1.54
|
|
5
|
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.
|
Cancer Lett
|
1999
|
1.52
|
|
6
|
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
|
Oncogene
|
2001
|
1.25
|
|
7
|
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs.
|
J Clin Invest
|
2000
|
1.22
|
|
8
|
Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
|
J Cell Biochem
|
1997
|
1.16
|
|
9
|
The role of half-transporters in multidrug resistance.
|
J Bioenerg Biomembr
|
2001
|
1.04
|
|
10
|
Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.
|
Genes Chromosomes Cancer
|
1998
|
0.99
|
|
11
|
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
|
Cancer
|
2001
|
0.98
|
|
12
|
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
|
J Clin Oncol
|
2001
|
0.91
|
|
13
|
FR901228 causes mitotic arrest but does not alter microtubule polymerization.
|
Anticancer Drugs
|
2000
|
0.88
|
|
14
|
Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.
|
Mol Pharmacol
|
1998
|
0.85
|
|
15
|
Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells.
|
Cancer Res
|
2000
|
0.83
|
|
16
|
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
|
Blood
|
1995
|
0.83
|
|
17
|
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
|
Int J Oncol
|
2001
|
0.82
|
|
18
|
Clinical reversal of multidrug resistance.
|
Stem Cells
|
1996
|
0.81
|
|
19
|
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
|
Carcinogenesis
|
1996
|
0.79
|